发布求助
文献互助 智能选刊 最新文献

BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation最新文献

筛选
英文 中文
HIV/HCV coinfection: a new era of treatment. HIV/HCV合并感染:治疗的新时代。
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2011-09-01
Liz Highleyman
{"title":"HIV/HCV coinfection: a new era of treatment.","authors":"Liz Highleyman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hepatitis C is a life-threatening illness that can progress to cirrhosis, liver cancer, and end-stage liver failure. An estimated one-third of HIV positive people are coinfected with hepatitis C virus (HCV), and HCV-related liver disease is a major cause of death for people with HIV in the era of effective antiretroviral therapy (ART). HCV has made headlines recently due to the approval of the first direct-acting antiviral (DAA) agents, which promise to revolutionize hepatitis C treatment. Researchers at the 2011 Conference on Retroviruses and Opportunistic Infections (CROI) and the Infectious Disease Society of America (IDSA) annual meeting presented the first data from studies of these drugs in HIV/HCV coinfected people.</p>","PeriodicalId":80644,"journal":{"name":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","volume":"23 4","pages":"30-47"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30601800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rilpivirine and complera: new first-line treatment options. 利匹韦林和复合物:新的一线治疗选择。
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2011-09-01
Reilly O'Neal
{"title":"Rilpivirine and complera: new first-line treatment options.","authors":"Reilly O'Neal","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Two antiretroviral medicines recently came on the scene for people starting HIV treatment for the first time: Rilpivirine (brand name Edurant) won marketing approval in May, and the following August saw approval of Complera, a single-pill once-daily regimen that joins rilpivirine with two other drugs. This article explains the science behind rilpivirine and Complera and how these drugs measure up to the commonly prescribed efavirenz (Sustiva) and Atripla. lines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, published by the U.S. Department of Health and Human Services (DHHS), currently lists efavirenz plus tenofovir/emtricitabine as the \"preferred\" NNRTI-based regimen for people starting antiretroviral therapy (ART) for the first time. In fact, the DHHS guidelines have listed efavirenz as a component of preferred starter regimens since 1998--a reflection of the drug's potency and long-lasting effects. Yet efavirenz has downsides, most famously its association with central nervous system side effects like dizziness</p>","PeriodicalId":80644,"journal":{"name":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","volume":"23 4","pages":"14-8"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30601802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding and managing peripheral neuropathy. 理解和治疗周围神经病变。
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2010-12-01
Anne Monroe
{"title":"Understanding and managing peripheral neuropathy.","authors":"Anne Monroe","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Peripheral neuropathy is the most common neurological disorder in people with HIV infection. It can be a major source of pain and discomfort and a limiting factor in antiretroviral treatment. Since the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, the overall incidence of neurological complications of HIV--such as HIV-associated dementia and central nervous system opportunistic infections--has decreased, however, rates of peripheral nervous system complications remain high.</p>","PeriodicalId":80644,"journal":{"name":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","volume":"22 2","pages":"27-35"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29430682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammation, immune activation, and HIV. 炎症，免疫激活和HIV。
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2010-12-01
Liz Highleyman
{"title":"Inflammation, immune activation, and HIV.","authors":"Liz Highleyman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Inflammation is a broad term for what happens in the body when the immune system is activated to counter a threat. A healthy immune response is key to good health, but ongoing immune activation and inflammation due to a persistent threat such as chronic HIV infection can lead to many different problems throughout the body.</p>","PeriodicalId":80644,"journal":{"name":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","volume":"22 2","pages":"12-26"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29430882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HIV and the recession: staying well in tough times. 艾滋病和经济衰退:在困难时期保持健康。
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2010-12-01
Heather Boerner
{"title":"HIV and the recession: staying well in tough times.","authors":"Heather Boerner","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":80644,"journal":{"name":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","volume":"22 2","pages":"41-51"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29430879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
KP-1461: a novel anti-HIV drug in limbo? KP-1461:一种悬而未决的新型抗hiv药物?
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2010-12-01
David Evans
{"title":"KP-1461: a novel anti-HIV drug in limbo?","authors":"David Evans","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The path of an experimental drug from the laboratory to U.S. Food and Drug Administration (FDA) approval is typically long, rocky, and uncertain. It is especially so for a drug that turns common wisdom on its head. Take KP-1461, a new type of antiretroviral drug from Koronis Pharmaceuticals in Seattle. Unlike all of the currently approved anti-HIV drugs, which aim to reduce the amount of virus in the body by blocking viral replication, KP-1461 was designed not to inhibit replication, but rather to force newly created HIV to become less able to infect human cells.</p>","PeriodicalId":80644,"journal":{"name":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","volume":"22 2","pages":"9-11"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29430872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hormonal contraception for HIV positive women. 艾滋病毒阳性妇女的激素避孕。
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2010-12-01
Jennifer Cocohoba
{"title":"Hormonal contraception for HIV positive women.","authors":"Jennifer Cocohoba","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Barrier methods such as condoms and diaphragms are the most commonly used forms of birth control among HIV positive women. Sterilization is the second most popular method and hormonal contraception is the third Hormonal contraceptives, when used correctly and consistently, are highly effective in preventing unintended pregnancy and are also useful for treating health conditions such as painful menstruation.</p>","PeriodicalId":80644,"journal":{"name":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","volume":"22 2","pages":"36-40"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29430877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A glass half full: cancer risk for people living with HIV. 半杯水:艾滋病毒携带者患癌症的风险。
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2010-06-01
John-Manuel Andriote
{"title":"A glass half full: cancer risk for people living with HIV.","authors":"John-Manuel Andriote","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":80644,"journal":{"name":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","volume":"22 4","pages":"30-41"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40090960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The iPrEx results: lifting hopes, raising questions. iPrEx的结果:带来了希望，也提出了问题。
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2010-06-01
Judith D Auerbach
{"title":"The iPrEx results: lifting hopes, raising questions.","authors":"Judith D Auerbach","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":80644,"journal":{"name":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","volume":"22 4","pages":"47-9"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40090363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tesamorelin update. 特萨莫林更新。
BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation Pub Date : 2010-06-01
Reilly O'Neal
{"title":"Tesamorelin update.","authors":"Reilly O'Neal","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":80644,"journal":{"name":"BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation","volume":"22 4","pages":"16-9"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40090958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信